Biopolym. Cell. 1999; 15(6):538-542.
http://dx.doi.org/10.7124/bc.00054B
Molecular Mechanisms of Differentiation
Analysis of protein-protein interactions mediated by adaptor protein Grb2 during the course of megakaryocytic differentiation of human erythroleukemia cell line K562
1Il'nytska O. M., 1Palyvoda O. Yu., 1Gusak Z. M., 1Val'ovka T. I., 1Igumentseva N. I., 1Kusen' S. I., 1Drobot L. B.
  1. Division of Cell Regulatory Systems of O.V. Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine
    14/16, Drahomanov Str., Lviv, Ukraine, 79005

Abstract

Protein-protein interactions mediated by adaptor protein Grb2 during the course of PMA-induced megakaryocytic differentiation of the human erythroleukemia cell line H562 were studied. Binding assay was performed in vitro using the recombinant forms of Grb2, (Crb2/full, Grb2/N-SH3 and Grb2/C-SH3), conjugated with glutathione-S-transferase. Proteins, binding of which are modulated in differentiated cells, were identified and binding dynamics was analysed. It is supposed that a set of Grb2 targets could be used in common in signalling pathways involved in both the stimulation of mitogenesis and the induction of differentiation in the K562 cells.
Full text: (PDF, in Ukrainian)

References

[1] Pawson T, Schlessingert J. SH2 and SH3 domains. Curr Biol. 1993;3(7):434-42.
[2] van der Geer P, Pawson T. The PTB domain: a new protein module implicated in signal transduction. Trends Biochem Sci. 1995;20(7):277-80.
[3] Rowley PT, Ohlsson-Wilhelm BM, Farley BA, LaBella S. Inducers of erythroid differentiation in K562 human leukemia cells. Exp Hematol. 1981;9(1):32-7.
[4] Long MW, Heffner CH, Williams JL, Peters C, Prochownik EV. Regulation of megakaryocyte phenotype in human erythroleukemia cells. J Clin Invest. 1990;85(4):1072-84.
[5] Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75(1):175-85.
[6] Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13(4):764-73.
[7] Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem. 1996;271(38):23255-61.
[8] Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995;82(6):981-8.
[9] Jain SK, Langdon WY, Varticovski L. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene. 1997;14(18):2217-28.
[10] Tari AM, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun. 1997;235(2):383-8.
[11] Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A. 1995;92(24):10889-93.
[12] Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83(2):346-56.
[13] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
[14] Gorg A., Poslet W., Weser J. Horizontal SDS electrophoresis in ultrathin pore-gradient gels for the analysis of urinary proteins. Sci. Tools. 1985; 32 (1):5-9.
[15] Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 1994;13(24):5887-95.
[16] Mandanas RA, Boswell HS, Lu L, Leibowitz D. BCR/ABL confers growth factor independence upon a murine myeloid cell line. Leukemia. 1992;6(8):796-800.
[17] Rowley PT, Keng PC, Kosciolek BA. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk Res. 1996;20(6):473-80.
[18] Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 1996;13(12):2589-94.
[19] Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med. 1997;129(6):584-91.
[20] Cambier N, Zhang Y, Vairo G, Kosmopoulos K, Metcalf D, Nicola NA, Elefanty AG. Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation. Oncogene. 1999;18(2):343-52.